← Leaderboards
Hansell H Stedman
University Of Pennsylvania
$13,592,979
Attributed
$13,592,979
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,592,979 · 7
By mechanism
R01$7,675,287 · 2
U01$5,188,900 · 2
S10$480,500 · 1
M01$248,292 · 1
P01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- William A. Beltran$14,525,140
- Ronald G Collman$30,299,814
- Krista H Vandenborne$30,884,872
- Hugh Lee Sweeney$44,337,022
- Nicola J Mason$7,580,948
Others in their field
Top investigators on “Dystrophin”
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$43,696,384
- James M Ervasti · University Of Wisconsin Madison$18,166,626
- Elizabeth M McNally · University Of Chicago$15,033,035
- Kevin M Flanigan · Research Inst Nationwide Children'S Hosp$14,737,619
- Krista H Vandenborne · University Of Pennsylvania$13,932,898
- Dongsheng Duan · University Of Florida$13,861,127
Research focus
DystrophinGene TherapyMuscleAdeno-Associated Viral VectorMuscular DystrophiesDesignVectorUtrophinDoseTreatment EfficacyProteinsBaseGene TransferCanis FamiliarisMuscle FibersMuscle StrengthProgramsClinical ResearchClinical TrialsTransgenesInnovationMuscular DystrophyResponseDependovirus
Grant awards (30)
IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trials$1,620,242
U01 · FY2025 · NS · contact PI
IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trials$1,541,019
U01 · FY2024 · NS · contact PI
Safety and Efficacy of Systemic Gene Therapy in Informative Models for DMD$566,250
R01 · FY2019 · NS · contact PI
Safety and Efficacy of Systemic Gene Therapy in Informative Models for DMD$572,291
R01 · FY2018 · NS · contact PI
Safety and Efficacy of Systemic Gene Therapy in Informative Models for DMD$571,144
R01 · FY2017 · NS · contact PI
Safety and Efficacy of Systemic Gene Therapy in Informative Models for DMD$571,527
R01 · FY2016 · NS · contact PI
Safety and Efficacy of Systemic Gene Therapy in Informative Models for DMD$578,786
R01 · FY2015 · NS · contact PI
Systemic molecular therapy for muscular dystrophy$548,843
R01 · FY2013 · NS · contact PI
Systemic molecular therapy for muscular dystrophy$582,463
R01 · FY2012 · NS · contact PI
Systemic molecular therapy for muscular dystrophy$582,547
R01 · FY2011 · NS · contact PI
Translational program for molecular therapeutics in DMD$1
U01 · FY2011 · NS · contact PI
Systemic molecular therapy for muscular dystrophy$601,324
R01 · FY2010 · NS · contact PI
Shared Resource for Disease Model Surgical Critical Care and Data Mangement$480,500
S10 · FY2010 · RR · contact PI
Translational program for molecular therapeutics in DMD$1
U01 · FY2010 · NS · contact PI
Systemic molecular therapy for muscular dystrophy$626,768
R01 · FY2009 · NS · contact PI
Translational program for molecular therapeutics in DMD$1
U01 · FY2009 · NS · contact PI
Translational program for molecular therapeutics in DMD$983,535
U01 · FY2008 · NS · contact PI
Translational program for molecular therapeutics in DMD$1,044,101
U01 · FY2007 · NS · contact PI
Surgical Approaches to Systemic Gene Transfer$367,592
R01 · FY2006 · NS · contact PI
Surgical Approaches to Systemic Gene Transfer$376,438
R01 · FY2005 · NS
Surgical Approaches to Systemic Gene Transfer$376,438
R01 · FY2004 · NS
Surgical Approaches to Systemic Gene Transfer$376,438
R01 · FY2003 · NS
Surgical Approaches to Systemic Gene Transfer$376,438
R01 · FY2002 · NS
GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTORPHY$124,146
M01 · FY2002 · RR
GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTORPHY$124,146
M01 · FY2001 · RR
GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTORPHY$0
M01 · FY2001 · RR
GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTORPHY$0
M01 · FY2000 · RR
VIRAL DELIVERY INTO NEONATAL AND ADULT MAMMALS$0
P01 · FY2000 · AR
GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTORPHY$0
M01 · FY2000 · RR
GENE THERAPY FOR LIMB GIRDLE MUSCULAR DYSTORPHY$0
M01 · FY2000 · RR